Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.429
Filtrar
2.
Pharmacoeconomics ; 40(Suppl 2): 121, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36504379
6.
Medicine (Baltimore) ; 101(41): e31036, 2022 Oct 14.
Artigo em Inglês | MEDLINE | ID: mdl-36253977

RESUMO

BACKGROUND: Coronary heart disease (CHD) is a cardiovascular disease caused by myocardial ischemia. In China, safflor yellow and artemisinin-based combination therapies have been extensively used to treat angina pectoris. METHODS: Efficacies were provided by a network meta-analysis following the PRISMA 2020 checklist. Cost-effectiveness analysis was based on patient perspectives. Two-way and probabilistic sensitivity analyses were conducted to assess the robustness of the study results. RESULTS: Conventional treatment combined with safflower is a better choice against angina pectoris. Sensitivity analysis showed that the model was sensitive to the treatment efficacy rather than the drug cost. CONCLUSION: Conventional treatment combined with safflower injection is suggested to treat angina pectoris. Low molecular weight heparin or compound Danshen-dropping pills can be used to increase the recovery rate of angina pectoris, according to conventional treatment combined with safflower injection.


Assuntos
Artemisininas , Medicamentos de Ervas Chinesas , Angina Pectoris/tratamento farmacológico , Artemisininas/uso terapêutico , Medicamentos de Ervas Chinesas/uso terapêutico , Farmacoeconomia , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Metanálise em Rede
7.
Am J Manag Care ; 28(10): e351-e354, 2022 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-36252174

RESUMO

Pharmacoeconomic analyses are an important and useful guide for understanding a pharmacotherapeutic intervention's financial impact for relevant stakeholders. One type of pharmacoeconomic analysis that assesses a pharmacotherapeutic intervention's short-term financial implications is a budget impact analysis. Although methodology guidelines for budget impact analyses in the United States currently exist, not much guidance is available for analyses that are being conducted of rare or ultrarare disease states. In this article, we propose conducting a scenario analysis for pharmacotherapeutic interventions to treat rare diseases by varying health plan sizes to indicate what the potential plan impact would be if 1 member in said health plan received treatment. We then walk through an illustrative example and discuss the rationale for it.


Assuntos
Orçamentos , Doenças Raras , Farmacoeconomia , Humanos , Doenças Raras/tratamento farmacológico , Estados Unidos
8.
Ter Arkh ; 94(7): 850-858, 2022 Aug 12.
Artigo em Russo | MEDLINE | ID: mdl-36286942

RESUMO

AIM: To evaluate the budgetary impact of using budesonide + formoterol (Symbicort Turbuhaler) as maintenance therapy in real clinical practice compared with standard therapy for asthma of varying severity: for mild asthma with on-demand salbutamol; for moderate and severe asthma with the drug salmeterol + fluticasone and salbutamol on demand. MATERIALS AND METHODS: A static mathematical model was built to assess the impact on the budget when introducing the drug budesonide + formoterol (Symbicort Turbuhaler) in the treatment of asthma into clinical practice from the point of view of the state. Demographic data was taken from the official data of the Federal State Statistics Service. Direct medical costs included the cost of medicines, the cost of hospitalization of patients associated with the development of asthma exacerbations, and the cost of scheduled outpatient visits. Indirect costs considered the loss of GDP due to hospitalization of patients against the background of asthma exacerbations. A one-way sensitivity analysis was performed to confirm the robustness of the study results. RESULTS: Assessment of direct costs in the treatment of mild, moderate and severe asthma showed that a gradual increase in the proportion of patients receiving the drug budesonide + formoterol (Symbicort Turbuhaler) over the years to 5.5, 7.7 and 9.7% accordingly, led to an increase in the cost of pharmacotherapy over 3 years by 1.7 billion rubles, while direct non-drug costs associated with the treatment of complications that developed during the treatment of asthma decreased by 8.3 billion rubles. Thus, the reduction in total direct costs amounted to RUB 6.7 billion. At the same time, indirect costs decreased by 6.0 billion rubles. The total reduction in all costs (direct and indirect) when switching patients to budesonide + formoterol (Symbicort Turbuhaler) amounted to 12.5 billion rubles. In addition, the use of the drug budesonide + formoterol (Symbicort Turbuhaler) resulted in a decrease in the number of exacerbations: in the first year by 3137, in the second by 4393 and in the third by 5534 cases. A total of 13 064 asthma exacerbations were prevented over 3 years. CONCLUSION: Increasing the proportion of patients with asthma of varying severity receiving therapy with budesonide + formoterol (Symbicort Turbuhaler) will reduce the financial burden on both the healthcare system and the budgetary system.


Assuntos
Asma , Combinação Budesonida e Fumarato de Formoterol , Humanos , Combinação Budesonida e Fumarato de Formoterol/uso terapêutico , Fumarato de Formoterol/uso terapêutico , Budesonida/efeitos adversos , Broncodilatadores/uso terapêutico , Farmacoeconomia , Etanolaminas/efeitos adversos , Combinação de Medicamentos , Asma/tratamento farmacológico , Albuterol/efeitos adversos , Combinação Fluticasona-Salmeterol/uso terapêutico , Atenção à Saúde , Administração por Inalação
9.
Zhongguo Zhong Yao Za Zhi ; 47(18): 5106-5112, 2022 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-36164921

RESUMO

This study aims to investigate the efficacy, safety, and cost-effecctiveness of Qizhi Weitong Granules in the treatment of functional dyspepsia. Specifically, two commonly used clinical protocols for the treatment of functional dyspepsia were selected: Qizhi Weitong Granules+Mosapride vs Mosapride alone(control). Meta-analysis of previous clinical studies was performed to examine the efficacy and safety, and pharmacoeconomic evaluation was carried out according to the results of the Meta-analysis. The cost-effectiveness analysis was carried out to elucidated the incremental cost-effectiveness ratio(ICER), and the sensitivity was analyzed with tornado dia-gram and Monte Carlo simulation. The willingness-to-pay threshold of patients for functional dyspepsia was investigated and compared with the ICER to evaluate whether Qizhi Weitong Granules was cost-effective. The result showed that the effective rate of Qizhi Weitong Granules combined with Mosapride in the treatment of functional dyspepsia was 95.49%, which was higher than that of Mosapride alone(73.30%)(OR=8.52, 95%CI[4.36, 16.64])(P<0.000 1). The two groups showed no significant difference in safety. The price of Qizhi Weitong Granules+Mosapride was higher than that of Mosapride alone. The ICER was 640.29 CNY, 1 506.67 CNY lower than the willingness-to-pay threshold. The sensitivity analysis showed that the analysis results were relatively stable. Thus, Qizhi Weitong Granules+Mosapride is safe, effective, and economical in the treatment of functional dyspepsia, which should be further promoted in clinical settings.


Assuntos
Dispepsia , Benzamidas , Análise Custo-Benefício , Dispepsia/tratamento farmacológico , Farmacoeconomia , Fármacos Gastrointestinais/uso terapêutico , Humanos , Morfolinas , Resultado do Tratamento
10.
Curr Pharm Teach Learn ; 14(9): 1193-1198, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-36154965

RESUMO

BACKGROUND AND PURPOSE: This study reports on the development of a new game designed specifically for a pharmacoeconomics course to meet three objectives: (1) identify four main types of pharmacoeconomic analyses, (2) understand different outcomes for each analysis, and (3) interpret findings of pharmacoeconomic analyses. EDUCATIONAL ACTIVITY AND SETTING: The game simulated real-world applicability of pharmacoeconomic analyses in a classroom setting using a candy theme. Groups of pharmacy students (N = 62) competed by building formularies that incorporated a minimum number of medications (candies) from each outcome category and at least two specialty services. Each medication and service were assigned a cost and rating according to the outcome associated with each analysis type. The following class session served as a debriefing to assess student perceptions using a written survey. Survey responses ranged from a score of 1 (strongly agree) to 5 (strongly disagree). A separate open-ended question collected feedback on the strengths and weaknesses of the game and analyzed into themes. FINDINGS: Student responses averaged 1.96 (SD = 1.1) for all questions. The highest rated question, "I attained the stated goals/objectives of this activity," scored 1.81 (SD = 1.1). Four overall themes emerged: engaging (n = 10), valuable (n = 19), confusing (n = 17), and disconnected (n = 8). Students highlighted the value of the gaming activity for providing practical, real-life examples to increase their understanding. SUMMARY: The design and application of gaming in a pharmacoeconomics course proved practical and valuable for student learning.


Assuntos
Assistência Farmacêutica , Farmácia , Estudantes de Farmácia , Farmacoeconomia , Humanos , Inquéritos e Questionários
13.
J Comp Eff Res ; 11(16): 1147-1149, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-35998008

RESUMO

In this latest update we highlight a recent International Society of Pharmacoeconomics and Outcomes Research Good Practice Report on machine learning (ML) for health economics and outcomes research. We specifically discuss use cases of ML that offer opportunities in the generation of evidence using real-world data, including improvements in the identification of study cohorts, confounder identification and adjustment and estimating treatment effect heterogeneity. Barriers to the wider adoption of ML methods are also discussed.


Assuntos
Farmacoeconomia , Medicina Baseada em Evidências , Tecnologia Biomédica , Humanos , Avaliação de Resultados em Cuidados de Saúde/métodos , Avaliação da Tecnologia Biomédica
14.
Expert Rev Pharmacoecon Outcomes Res ; 22(7): 1061-1070, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-35912498

RESUMO

INTRODUCTION: Considerable challenges in the economic evaluation of precision medicines have been mentioned in previous studies. However, they have not addressed how an economic assessment would be conducted based on basket trials (novel studies for evaluation of precision medicine effects) in which the included populations have specific biomarkers and various cancers. Since basket trial populations have remarkable heterogeneity, this study aims to investigate the concept of heterogeneity and specific method(s) for considering it in economic evaluations through guidelines and studies that could be applicable in economic evaluation based on basket trials. AREA COVERED: We searched PubMed, Web of Science, Scopus, Google Scholar, and Google to find studies and pharmacoeconomics guidelines. The inclusion criteria included subjects of patient heterogeneity and suggested explicit method(s). Thirty-nine guidelines and 43 studies were included and evaluated. None of these materials mentioned disease types in a target population as a factor causing heterogeneity. Moreover, in economic evaluations, patient heterogeneity has been considered with four general approaches subgroup analysis, individual-based models, sensitivity analysis, and regression models. EXPERT OPINION: Type of disease is not considered a contributing factor in population heterogeneity, and the probable appropriate method for this issue could be individual-based models.


Assuntos
Ensaios Clínicos como Assunto , Farmacoeconomia , Seleção de Pacientes , Medicina de Precisão , Ensaios Clínicos como Assunto/economia , Ensaios Clínicos como Assunto/métodos , Ensaios Clínicos como Assunto/estatística & dados numéricos , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/economia , Guias de Prática Clínica como Assunto , Medicina de Precisão/economia , Medicina de Precisão/métodos , Medicina de Precisão/estatística & dados numéricos
15.
Front Public Health ; 10: 940173, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36003637

RESUMO

This paper is based on financial data analysis of 241 listed pharmaceutical manufacturing enterprises in China, we study the different effects of different tax reduction policies on the financial performance of enterprises in the short term and long term. Through the verification of practical examples, it could be found that the implementation of a tax reduction policy can indeed play a positive role in the financial performance of enterprises, and the reduction of income tax significantly improves the short-term financial performance of enterprises. However, the tax reduction of turnover tax significantly enhances the long-term financial performance of enterprises, and the effect of tax reduction on the financial performance of state-owned enterprises is better than that of non-state-owned enterprises. Generally speaking, tax reduction policy has a better effect on the financial performance of non-state-owned enterprises and enterprises in central and western regions than state-owned enterprises and enterprises in eastern regions.


Assuntos
Farmacoeconomia , China
16.
Artigo em Inglês | MEDLINE | ID: mdl-35805521

RESUMO

The world is facing a continuous increase in medical costs. Due to the surge in disease prevalence, medical science is becoming more sensitive to the economic impact of medications and drug therapies. This brings about the importance of pharmacoeconomics, which is concerned with the effective use of health resources to optimize the efficiency and costs of medications of treatment for the best outcomes. This review was conducted to find out the potential barriers and facilitators to implementing pharmacoeconomic studies in the Middle Eastern region having both high- and low-income countries. The varying economies in the region depict diverse healthcare systems where implementation of pharmacoeconomics faces a large number of challenges and is also aided by numerous facilitators that contribute to the growth of its implementation. In this context, we have reviewed the status of pharmacoeconomics in Middle Eastern countries in research databases (Google Scholar, MEDLINE, Science Direct and Scopus) using keywords ("pharmacoeconomics", "barriers", "facilitators", "Middle East"). The study reported that Yemen, Syria, Palestine, Iran, Iraq, Jordan and Lebanon are the lowest-income countries in the Middle East and the implementation of pharmacoeconomics is the poorest in these states. The UAE, Saudi Arabia and Israel are high-income rich states where economic aspects were comparatively better but still a large number of barriers hinder the way to its effective implementation. These include the absence of national governing bodies, the lack of data on the effectiveness of medications, the absence of sufficient pharmacoeconomic experts and the lack of awareness of the importance of pharmacoeconomics. The main facilitators were the availability of pharmacoeconomic guidelines, the encouragement of pharmacoeconomic experts and the promotion of group discussions and collaborations between researchers and policymakers. Cost-benefit analysis is still evolving in Middle Eastern countries, and there is a great need for improvement so that states can effectively benefit from cost analysis tools and utilize their health resources. In this regard, governments should develop national governing bodies to evaluate, implement pharmacoeconomics at the local and state levels and bring about innovation in the field through further research and development incorporating all sectors of pharmacy and pharmaceutics. The data presented in this research can further be extended in future studies to cover the various domains of pharmacoeconomics including cost-minimization analysis, cost-effectiveness analysis and cost-benefit analysis and their applications within the healthcare sectors of Middle Eastern countries.


Assuntos
Farmacoeconomia , Pesquisadores , Análise Custo-Benefício , Humanos , Líbano , Síria
17.
Zhongguo Zhong Yao Za Zhi ; 47(14): 3950-3955, 2022 Jul.
Artigo em Chinês | MEDLINE | ID: mdl-35850854

RESUMO

Chronic rhinosinusitis refers to the non-specific inflammation that occurs in the nasal mucosa and sinuses, with clinical manifestations of mucopurulent nasal discharge, nasal congestion, hyposmia or anosmia, and head and face swelling pain.This disease has a long course and is prone to recurrence, which seriously affects the physical and mental health and quality of life of patients.Xiangju Capsules, prepared from infructescence of Platycarya strobilacea(without seeds), Prunellae Spica, Magnoliae Flos, Chuan-xiong Rhizoma, Angelicae Dahuricae Radix, Chrysanthemi Indici Flos, Astragali Radix, etc., are effective in dispelling wind by pungency and dispersing, clearing heat, and relieving orifices, and has good efficacy and safety in the clinical treatment of acute and chronic rhinosinusitis and rhinitis.From the perspective of the health system, an economic evaluation model was constructed based on the Meta-analysis of the effectiveness of Xiangju Capsules in the treatment of chronic rhinosinusitis to discuss the economic efficiency of Xiangju Capsules in combination with conventional treatment or conventional treatment alone in patients with chronic rhinosinusitis.The model simulation results showed that 53 days(average course of treatment) after treatment, Xiangju Capsules combined with conventional treatment had higher cost and higher output, with an incremental cost-effectiveness ratio of CNY 263.71, about 0.82% of per capita disposable income.As revealed by sensitivity analysis results, the research results were robust.As indicated by the findings of this study, Xiangju Capsules combined with conventional treatment for chronic rhinosinusitis patients were more economical than conventional treatment alone based on the assumption that the per capita disposable income of Chinese people in 2020 was the threshold of patients' willingness to pay.


Assuntos
Pólipos Nasais , Rinite , Sinusite , Doença Crônica , Farmacoeconomia , Humanos , Pólipos Nasais/tratamento farmacológico , Qualidade de Vida , Rinite/tratamento farmacológico , Sinusite/tratamento farmacológico
18.
Ars pharm ; 63(3): 294-305, Jul. - sept. 2022. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-208758

RESUMO

Introduction: Chondroitin sulfate was proposed as a more appropriate strategy for osteoarthritis long-term management than conventional treatment (nonsteroidal anti-inflammatory drugs and acetaminophen). However, its efficacy has been widely discussed and its public financing by the Spanish National Health System has been questioned. The aim of this paper was review on the clinical and economic aspects of chondroitin sulfate in osteoarthritis treatment. Method: A bibliographic search of recent literature was carried out until March 9th, 2022. The databases used were MEDLINE and Scopus. Results: According to the set of clinical studies identified in the search, chondroitin sulfate was effective in reducing cartilage volume loss, its clinical effects were estimated by objective (magnetic resonance or specific biomarkers) and subjective (visual analog pain scale or Lequesne index) outcome measures. In the set of studies reviewed, chondroitin sulfate proved to be an acceptable therapeutic option in clinical terms. Regarding economic aspects, only one study was identified, according to which, the prescription of chondroitin sulfate implies a lower cost per patient compared to non-steroidal anti-inflammatory drugs. Conclusion: From the clinical and economic points of view, the findings of this brief review justify the presence of chondroitin sulfate in osteoarthritis guidelines. (AU)


Introducción: El sulfato de condroitina fue propuesto como una estrategia más apropiada para el manejo de la artrosis a largo plazo que los tratamientos convencionales (antiinflamatorios no esteroideos y paracetamol). Sin embargo, su eficacia ha sido ampliamente discutida y su financiación por el Sistema Español de Salud cuestionado. El objetivo de este trabajo fue realizar revisar los aspectos clínicos y económicos en el manejo del sulfato de condroitina en el tratamiento de la artrosis. Método: Se llevo a cabo una búsqueda de la literatura reciente hasta el 9 de marzo de 2022. Las bases de datos consultadas fueron MEDLINE y Scopus. Resultados: Según el conjunto de los estudios identificados, el sulfato de condroitina fue efectivo en la reducción de pérdida de volumen de cartílago causante del dolor y la rigidez articular. Sus efectos clínicos fueron estimados mediante medidas de resultado objetivas (resonancias magnéticas o biomarcadores específicos) y subjetivas (escala visual analógica de dolor o índice de Lequesne). El sulfato de condroitina mostró ser una opción terapéutica aceptable en términos clínicos. Respecto a los aspectos económicos, solo se identificó un estudio, según el cual, la prescripción de sulfato de condroitina implica un menor coste por paciente comparado con antiinflamatorios no esteroideos. Conclusión: Desde los puntos de vista clínico y económico, los hallazgos de esta breve revisión justifican la presencia del sulfato de condroitina en las guías medicas del manejo de la artrosis. (AU)


Assuntos
História do Século XXI , Farmacoeconomia , Sulfatos de Condroitina , Artropatias , Bases de Dados Bibliográficas , Bases de Dados como Assunto , Espectroscopia de Ressonância Magnética
19.
Value Health Reg Issues ; 30: 168-169, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35696900
20.
Artigo em Inglês | MEDLINE | ID: mdl-35742766

RESUMO

OBJECTIVE: This study assessed the differentiation of treatment costs with newer and older antiepileptic drugs (AEDs) through its correlation with treatment effectiveness and an adverse event (AE) in pediatric patients with epilepsy (PPE). METHODS: PPE on monotherapy of AEDs for the last 6 months were screened for this study. Seizure frequency during the study was compared with that within 6 months before the study. The following parameters were also assessed: quality of life in epilepsy, Pittsburgh Sleep Quality Index, and Liverpool AEs Profile. An incremental cost-effectiveness ratio (ICER) analysis based on the costs of pharmacotherapy was also performed. RESULTS: Out of 80 PPE, 67 completed the study, and 13 PPE were lost after failing to meet the inclusion criteria. A total of 56.71% of PPE were on newer AEDs, and 43.28% were on older AEDs. Newer and older AEDs did not differ significantly in seizure frequency reduction and quality of life parameters, although these were improved significantly during the study period. As per ICER, newer AEDs need an additional EUR 36.82 per unit reduction in seizure frequency. CONCLUSION: Newer AEDs have comparatively better efficacy, although not significantly better than older AEDs. However, the additional cost per unit improvement is quite high with newer AEDs, necessitating pharmacoeconomic consideration in pediatric epilepsy treatment.


Assuntos
Anticonvulsivantes , Epilepsia , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/uso terapêutico , Criança , Farmacoeconomia , Epilepsia/induzido quimicamente , Epilepsia/tratamento farmacológico , Humanos , Qualidade de Vida , Convulsões/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...